On the stock market since 2005, it operates in the world of health and science. It has 32,698 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $9.3B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 19% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 14% a year on average.
It pays out $2.92 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, CMXHF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CMXHF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.